about
CCL3L1 copy number is a strong genetic determinant of HIV seropositivity in Caucasian intravenous drug usersCCR5 haplotypes influence HCV serostatus in Caucasian intravenous drug usersGeographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysisCorrection: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-AnalysisClinical and pathological findings of fatal 2009-2010 pandemic influenza A (H1N1) infection in Estonia.Clinical parameters predicting failure of empirical antibacterial therapy in early onset neonatal sepsis, identified by classification and regression tree analysis.Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies.Comparison of two alternative study designs in assessment of medicines utilisation in neonates.Association between HIV-1 tropism and CCR5 human haplotype E in a Caucasian population.The development of gut microbiota in critically ill extremely low birth weight infants assessed with 16S rRNA gene based sequencing.Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration.Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children.Hospitalised neonates in Estonia commonly receive potentially harmful excipients.Framework conditions facilitating paediatric clinical research.First report of Wohlfahrtiimonas chitiniclastica from soft tissue and bone infection at an unusually high northern latitude.Meropenem vs standard of care for treatment of late onset sepsis in children of less than 90 days of age: study protocol for a randomised controlled trial.High variability in the dosing of commonly used antibiotics revealed by a Europe-wide point prevalence study: implications for research and dissemination.Gut colonization by aerobic microorganisms is associated with route and type of nutrition in premature neonates.Pharmacokinetics of penicillin g in very-low-birth-weight neonates.A CCL5 Haplotype Is Associated with Low Seropositivity Rate of HCV Infection in People Who Inject DrugsShort versus long infusion of meropenem in very-low-birth-weight neonatesCoagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?Use of oral fluid to examine the molecular epidemiology of varicella zoster virus in the United Kingdom and continental Europe.Treatment of scedosporiosis with voriconazole: clinical experience with 107 patientsThe impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment.Peripheral blood RNA gene expression profiling in patients with bacterial meningitis.Antibiotic prescription preferences in paediatric outpatient setting in Estonia and Sweden.Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and InfantsPeople living with HIV in Estonia: engagement in HIV care in 2013.Transmitted drug resistance is still low in newly diagnosed human immunodeficiency virus type 1 CRF06_cpx-infected patients in Estonia in 2010Understanding pharmacokinetics/pharmacodynamics in managing neonatal sepsis.Association between TLR3 rs3775291 and resistance to HIV among highly exposed Caucasian intravenous drug usersOff label use of prescription medicines in children in outpatient setting in Estonia is common.Antibiotic therapy for pediatric community-acquired pneumonia: do we know when, what and for how long to treat?Pharmacokinetics and pharmacodynamics of oseltamivir in neonates, infants and children.New antibiotics for paediatric use: a review of a decade of regulatory trials submitted to the European Medicines Agency from 2000--why aren't we doing better?Clinical trials in neonatal sepsis.Treatment option for sepsis in children in the era of antibiotic resistance.Harmonisation in study design and outcomes in paediatric antibiotic clinical trials: a systematic review.Plasmid with Colistin Resistance Gene mcr-1 in Extended-Spectrum-β-Lactamase-Producing Escherichia coli Strains Isolated from Pig Slurry in Estonia.
P50
Q27491039-9F59309C-C599-43A6-9967-E5F0BF53BB8EQ28534869-9CB5AF0C-70FE-42D6-8D66-D333F7241F9CQ28545866-9F71205F-0EE7-4DDB-A37A-681B94903F74Q28547717-6EB7FBD0-E468-41BA-BEAF-6BE3093B9BF9Q30413560-3BED464E-8B10-47A7-B896-8F181F08E050Q30908704-F9A64CB2-4118-44A4-9A4E-77C050C2ED4BQ33392206-814F943B-580E-4258-A91A-DDF30095AF64Q33946255-4B8CED19-F5C9-4F7E-8910-6FA0BFCC9949Q34098010-1D945463-E094-4962-A496-8A9606B86BC0Q34129339-A18B737A-E007-4C57-9858-29563203CFDDQ34141420-9295415E-9DA1-489A-B2A0-E04E2B09A1C7Q34150923-B703A241-875D-4D86-AA90-033D88B47870Q34397214-3334DC27-E87B-4E44-8B9C-C759BAC25B59Q34662520-535A83F0-D6F0-4946-B22B-4F7207A2E676Q35317716-BD1EECA1-CC0E-4EBD-A051-B5C2EBA20225Q35352859-7F5D1056-1569-4969-9D3F-253FEF102E0CQ35532010-31149327-0AFA-4ACB-B134-11ABABB27EA5Q35617208-848CBD41-650F-4473-A802-707A24F9E052Q35840847-6426D9EE-54C4-4819-959E-A95EE435FC1BQ36053084-270493DD-5671-4BE4-ACF5-0C2DABBF00F0Q36172523-7733A06C-3FBC-4E40-A098-54C130961D51Q36216479-E9BE3180-341C-4B0C-B132-B6444DC440FCQ36547322-BB35152E-71FB-4D8D-870E-BF385D1D8D5FQ36593781-DA51B249-9F58-40F3-8A8C-9B98262A1E08Q36692642-F14DFC29-9F1C-4454-B3D2-F80469CB6402Q36693885-96D3B139-5634-442F-9F71-70BE9CC11564Q36824277-07C8D0EE-A505-4E46-B486-64068701F84EQ37120041-206A7A17-46A2-4116-A2EE-06883EBB735CQ37422068-6439AA96-CEE7-4AB1-802E-F0F6CA03617DQ37610641-36C85FCA-AEBE-415E-9C02-57E308EA986DQ37697469-75F118DA-299A-4C96-B478-B830D092E41AQ37725740-1B63AA5C-E3D0-45FA-8954-BB24DCE10650Q37854539-2D91948B-6953-4231-82F0-28DADA19A8D1Q37998869-1A6B5D05-5861-4F5E-AC69-C99BBDDCCB72Q38107016-CE7DDB15-8E99-4989-B46F-8F03273776C0Q38117916-AE386A4D-2CD7-4AF3-9988-168738B87E02Q38125671-9141809C-78AB-44A8-9446-F7A7AB6D749DQ38246118-F7DB75B2-682E-44F5-AD82-88E884621E70Q38885190-FABCE5B7-2AB2-4EB5-8E93-434D1944A758Q39443112-E84BA0EB-2059-4D00-8903-434A707B211E
P50
description
Forscher
@de
chercheur
@fr
eesti mikrobioloog ja viroloog
@et
hulumtuese
@sq
investigador
@es
researcher
@en
ricercatrice
@it
viroloog
@nl
հետազոտող
@hy
研究者
@zh
name
Irja Lutsar
@ast
Irja Lutsar
@en
Irja Lutsar
@es
Irja Lutsar
@et
Irja Lutsar
@nl
type
label
Irja Lutsar
@ast
Irja Lutsar
@en
Irja Lutsar
@es
Irja Lutsar
@et
Irja Lutsar
@nl
prefLabel
Irja Lutsar
@ast
Irja Lutsar
@en
Irja Lutsar
@es
Irja Lutsar
@et
Irja Lutsar
@nl
P21
P214
73149542597100300585
P2953
Irja_Lutsar
P31
P496
0000-0002-5082-429X
P569
1954-07-20T00:00:00Z
P735
P7859
viaf-73149542597100300585